

CROSS REFERENCE TO RELATED APPLICATIONS

The present application is the national phase of PCT application No. PCT/US99/13959, filed June 21, 1999, which is a continuation-in-part application of US application Serial No. 09/100,287 filed June 20, 1998.

At page 19, lines 2-9, re-align the residues as follows:

1	5	10	15
Asp-Leu-Ser-Asp-Leu-Lys-Gly-Leu-Leu-Leu-His-Lys-Leu-Asp-Gly-Leu			
Glu Ile	Glu Ile Arg	Ile Ile Ile	Arg Ile Glu Ile
Val	Val	Val Val Val	Val Val
Phe	Phe	Phe Phe Phe	Phe Phe

At page 35 line 5-20, please replace as follows:

The Th epitope is attached, optionally through spacer B, to either the N terminus or C terminus of the IgE-CH3 peptide and crossreactive and functional immunological analogs thereof. Preferred peptide immunogens of this invention are the peptides containing the IgE-CH3 domain antigen peptides (e.g., SEQ ID NO:5) (or immunological analogs thereof) and Th peptides, and optionally Inv (SEQ ID NO:13). In a more preferred embodiment the Th epitope is an HBs Th, HBc Th, MV_F Th, PT Th, TT Th, CT Th (e.g., SEQ ID NO:12) or artificial Th (SEQ ID NOS:9-11 and 60), or functional immunogenic analogue thereof, and optionally, A is Inv (SEQ ID NO:13) attached through a (B)_n spacer such as Gly-Gly or ([-N)L ys.

In the Claims

Please cancel claim 1, amend claims 2 and 19 and add claim 29 as follows:

29. (New) An IgE-CH3 domain antigen peptide useful for eliciting antibodies that inhibit the binding of IgE to basophils and mast cells said peptide is about 25 and about 29 amino acids in length cyclized with two cysteine residues separated by about 23 amino acid residues, the sequence of said peptide corresponds to AA413-AA435 of the epsilon heavy chain of a mammalian IgE-CH₃ and an analogue of the